Abstract
Asparaginase is an integral component of acute lymphoblastic leukemia (ALL) treatment in pediatric protocols. In high-income counties, pegylated asparaginase derived from the bacterium E. coli is used as first-line therapy. However, the drug is associated with many adverse effects such as hypersensitivity reaction, pancreatitis, thrombosis or hepatotoxicity, which might lead to omitting some doses required in the protocol. Erwinia chrysanthemi asparaginase can be used as a substitute for patients who develop hypersensitivity reaction on pegylated E. coli asparaginase. In this study, Gupta and his team compared the outcome of over 8000 patients who A) received all asparaginase doses according to the protocol, versus B) patients who switched to Erwinia asparaginase, versus C) patients who didn’t receive all asparaginase doses. According to their data, high risk and slow early response patients who didn’t receive all asparaginase doses had worse outcome compared to patients on E. coli or Erwinia asparaginase. Considering the size of the cohort, this is the largest study focusing on the impact of asparaginase discontinuation on the outcome among children with B-cell ALL.